Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
With
Eli Lilly and Company
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has been diagnosed with type 2 diabetes mellitus
Has hemoglobin-specific A1c fraction (HbA1c) of 7.1% to 11.0%, inclusive, at screening
Has a body mass index (BMI) of 25 kg/m2 to 45 kg/m2, inclusive, at screening
Has been treated with diet and exercise alone or in combination with a stable regimen of metformin (MET), a sulfonylurea (SU), a thiazolidinedione (TZD), a combination of metformin and an SU, a combination of metformin and a TZD, or a combination of an SU and a TZD for a minimum of 2 months prior to screening
Either is not treated with or has been on a stable treatment regimen with any of the following medications for a minimum of 2 months prior to screening:
* Hormone replacement therapy (female subjects)
* Oral contraceptives (female subjects)
* Antihypertensive agents
* Lipid-lowering agents
* Thyroid replacement therapy
* Antidepressant agents
* Drugs known to affect body weight, including prescription medications (e.g. orlistat \[XENICAL®\], sibutramine \[MERIDIA®\], topiramate \[TOPAMAX®\]) and over the counter antiobesity agents
You may not be if
Has ever been exposed to exenatide (exenatide once weekly \[exenatide LAR\], exenatide BID, BYETTA, or any other formulation) or any glucagon-like peptide-1 (GLP-1) analog
Has received any investigational drug within one month (or five half-lives of the investigational drug, whichever is greater) of screening
Has been treated, is currently being treated, or is expected to require or undergo treatment with any of the following treatment excluded medications:
* Any dipeptidyl peptidase 4 (DPP-4) inhibitor within 3 months prior to screening
* Alpha glucosidase inhibitor, meglitinide, nateglinide, or pramlintide (SYMLIN®) within 30 days of screening
* Insulin within 2 weeks of screening or for more than 1 week within 3 months of screening
* Systemic corticosteroids by oral, intravenous, or intramuscular route; or potent, inhaled, or intrapulmonary (including ADVAIR®) steroids known to have a high rate of systemic absorption
Clareo Health | A Study to Evaluate the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly in Subjects With Type 2 Diabetes Mellitus (DURATION-5)
